Yourgene Health Plc

Yourgene Health Plc, established in Manchester, UK, in 2000, operates as a molecular diagnostics firm specializing in the research, development, and commercialization of gene analysis technologies. These solutions primarily target prenatal screening and various other diagnostic applications, serving markets across the United Kingdom, continental Europe, and globally. Their product portfolio features a range of in vitro diagnostic tools, including the IONA Test, a non-invasive prenatal screening (NIPT) method for identifying Down's, Edwards', and Patau's syndromes in pregnant women. They also offer Cystic Fibrosis Screening tests, the Rapid Aneuploidy Analysis for confirmatory diagnosis post-amniocentesis, and a PCR assay for Recurrent Pregnancy Loss that diagnoses the six most common chromosomal abnormalities linked to miscarriage. Additionally, Yourgene provides DPYD genotyping products. Beyond specific tests, the company offers technological platforms like Ranger, designed for sample size selection and enrichment. Their Elucigene DPYD assay is a PCR test used to predict a patient's response to chemotherapy, and they provide the Clarigene SARS-CoV-2 CE-IVD, a PCR assay for routine COVID-19 testing. Yourgene Health also delivers comprehensive genomic services, alongside tools for sample preparation and analysis, bioinformatics, and software solutions. For clinical research organizations, they offer specialized services encompassing DNA, RNA/miRNA, and nucleonic extraction; quantification; genotyping; gene expression; methylation; and microarray analysis. The company, originally named Premaitha Health PLC, adopted its current identity as Yourgene Health Plc in November 2018.

Yourgene Health Plc trades as YGEN.L on LSE. The company is classified in Healthcare / Medical - Diagnostics & Research and reports in GBP.

The current profile places the business in Medical - Diagnostics & Research. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £37.56M of revenue and -£1.92M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Yourgene Health Plc can be compared against peers such as Advanced Oncotherapy plc, Celadon Pharmaceuticals Plc, Induction Healthcare Group PLC, LungLife AI, Inc., LungLife AI, Inc., MGC Pharmaceuticals Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £16.37M, beta of 0.86, and return on equity of -5.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

YGEN.L currently shows total debt of £19.11M and beta of 0.86. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.yourgene-health.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.